When Testing Leaves the State: What This Really Means for NJ Cannabis

By Matha Figaro

New Jersey’s cannabis market was designed to operate as a closed, intrastate regulatory system.

Cultivators grow here.
Manufacturers produce here.
Labs test here.
Retailers sell here.

Everything stays inside the state.

So when news broke that a licensed testing laboratory transported regulated cannabis samples out of New Jersey for testing, my reaction wasn’t outrage — it was concern.

Because this isn’t just about one lab.
It’s about system integrity.

1. Interstate Movement Is Not a Technical Violation

Cannabis remains federally illegal.
Interstate transport is federally prohibited.

That’s not controversial. That’s baseline.

New Jersey’s entire regulatory framework exists around a controlled, intrastate supply chain precisely because federal law hasn’t changed.

If regulated samples left the state, that’s not a paperwork issue.
It’s a structural contradiction of the model we were licensed under. And that should matter to every operator.

2. Chain of Custody Is Not Optional

Here’s the question that isn’t being discussed enough:

Did the cultivators and manufacturers who submitted those samples approve their product leaving the state?

Because if they didn’t, then compliant operators were exposed to federal risk without consent.

Testing labs are not independent contractors in a vacuum. They are regulated gatekeepers inside a controlled supply chain. When chain of custody breaks, trust breaks. And without trust, this market collapses.

3. Enforcement vs. Prevention

Suspensions and fines are enforcement tools. But enforcement after the fact doesn’t fix structural gaps.

If a licensed lab was able to move samples out of state, then one of two things happened:

• The rules were unclear
• The controls were weak
• Or oversight was insufficient

Punishment alone doesn’t answer which.

If METRC training or compliance training is being required after violations occur, that raises a different concern:

Why wasn’t that mandatory before activation?

Prevention must come before penalties. Otherwise, enforcement starts to look reactive instead of protective.

4. ISO & Testing Integrity

Laboratory compliance isn’t just about paperwork.
It is the backbone of consumer safety.

If reporting practices or accreditation standards are being questioned alongside custody issues, that compounds the problem.

Testing is the firewall between product and public consumption.

If we weaken testing oversight, we weaken everything.

5. The Bigger Policy Conversation

This is not about attacking the CRC.
It’s about strengthening the framework.

Operators are investing millions under the assumption that:

• The supply chain is intrastate
• Custody is controlled
• Oversight is consistent
• Enforcement is predictable

When those assumptions wobble, investor confidence wobbles. And when investor confidence wobbles, market stability follows.

6. What Needs to Happen Next

This moment requires clarity, not noise.

The Commission should issue formal written guidance addressing:

• Explicit prohibition (or clarification) of out-of-state sample handling
• Chain-of-custody consent requirements
• Lab audit transparency
• Mandatory pre-activation compliance training
• Clear corrective frameworks for future incidents

Not to shame anyone. But to strengthen the system.

Final Thought

New Jersey has built one of the most structured cannabis markets in the country.

We cannot afford sloppiness at the testing level.

Compliance is not optional. But enforcement must be structured, preventative, and transparent.

We don’t build legitimacy through headlines. We build it through airtight systems.